The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Genomic landscape and clinical outcomes of MDM2 amplifications in biliary tract cancers.
 
Fatema Nagib
No Relationships to Disclose
 
Sundas Nasir
No Relationships to Disclose
 
Aruj Dhyani
No Relationships to Disclose
 
Rohit Thummalapalli
Research Funding - Zai Lab (Inst)
 
Danny Khalil
Consulting or Advisory Role - Abbvie; Akamis Bio; PrimeFour Therapeutics
 
Olivia Heffernan
No Relationships to Disclose
 
Amin Yaqubie
No Relationships to Disclose
 
Henry Walch
No Relationships to Disclose
 
David Solit
Stock and Other Ownership Interests - Corramedical, Inc; Elsie Biotechnologies; Fore Biotherapeutics; Function Oncology; Melinda Therapeutics; Pyramid Biosciences; Scorpion Therapeutics; Vividion Therapeutics
Consulting or Advisory Role - BridgeBio Pharma; Corramedical; Elsie Biotechnologies; Fog Therapeutics; Fore Biotherapeutics; Function Oncology; Meliora Therapeutics; PAIGE.AI (I); Pfizer; Pyramid Biosciences; Rain Therapeutics; Scorpion Therapeutics; Vividion Therapeutics
 
Olca Basturk
No Relationships to Disclose
 
Nikolaus Schultz
Honoraria - OneOncology
 
Eileen O'Reilly
Consulting or Advisory Role - Abbvie (I); AstraZeneca; Autem Medical (I); Berry Genomics (I); BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Eisai (I); Exelixis (I); Genentech/Roche (I); Ipsen; J-Pharma (I); Merck; Merus; Novartis; QED Therapeutics (I); Revolution Medicines; SERVIER (I); Vector Health (I); Yiviva (I)
Research Funding - Agenus (Inst); Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Bristol Myers Squibb (Inst); Digestive Care (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Helsinn Healthcare (Inst); Parker Institute for Cancer Immunotherapy (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Revolution Medicines (Inst); Yiviva (Inst)
(OPTIONAL) Uncompensated Relationships - Thetis Pharma
 
Ghassan Abou-Alfa
Consulting or Advisory Role - Abbvie; Ability Pharma (I); Agenus (I); Alligator Bioscience (I); Arcus Ventures (I); Astellas Pharma (I); Astellas Pharma (I); AstraZeneca; Autem Medical; Berry Genomics; BioNtech (I); Boehringer Ingelheim (I); Bristol-Myers Squibb/Medarex (I); Fibrogen (I); Ipsen; J-Pharma; Merck Serono (I); Merus NV (I); Moma Therapeutics (I); Neogene Therapeutics (I); Novartis (I); Regeneron (I); Revolution Medicines (I); Roche/Genentech; Servier; Syros Pharmaceuticals (I); Tango Therapeutics (I); Tempus (I); Vector Health; Yiviva
Research Funding - Abbvie (Inst); Agenus (Inst); Arcus Ventures (Inst); AstraZeneca (Inst); Atara Biotherapeutics (Inst); Beigene (Inst); BioNtech (Inst); Bristol-Myers Squibb (Inst); Digestive Care (Inst); Elicio Therapeutics (Inst); Genentech/Roche (Inst); Helsinn Healthcare (Inst); Parker Institute for Cancer Immunotherapy (Inst); Pertzye (Inst); Yiviva (Inst)
 
Walid Chatila
No Relationships to Disclose
 
James Harding
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Cogent Medicine; Elevar Therapeutics; Exelixis; Jazz Pharmaceuticals; Merck; RayzeBio; SERVIER
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squibb Foundation (Inst); Jazz Pharmaceuticals (Inst); Kinnate Biopharma (Inst); Lilly (Inst); Tvardi Therapeutics (Inst); yivvia (Inst); Zymeworks (Inst)